Commentary|Videos|March 28, 2025
LEAP-001 Data for First-Line Lenvatinib/Pembrolizumab in Advanced Endometrial Cancer
Author(s)Christian Marth, MD, PhD, John Chan, MD
Christian Marth, MD, PhD, and John Chan, MD, discuss data for frontline lenvatinib plus pembrolizumab in advanced endometrial cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
First-line pembrolizumab monotherapy met the primary end point of PFS in dMMR advanced/recurrent endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
4
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
5